Navigation Links
Presentations at Leading Radiation Oncology Meeting Highlight CyberKnife Prostate Outcomes from Patients at More Than 40 Centers
Date:11/5/2012

, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 642 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical results and patient outcomes, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on September 10, 2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.  Accordingly, investors should not place undue reliance on any forward-look
'/>"/>

SOURCE Accuray Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Thoratec Announces Presentations At Upcoming Investor Conferences
2. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
3. Regeneron Announces September 2012 Investor Conference Presentations
4. Cynosure Announces Upcoming Conference Presentations
5. InterMune Announces Presentations of New Research in IPF at ERS
6. Cepheid to Webcast Upcoming Financial Presentations
7. Regeneron Announces June 2012 Investor Conference Presentations
8. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
9. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
10. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
11. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... , August 19, 2014 Elbit ... EMITF ) announced today that Elbit Medical Technologies ... Company in which it holds approximately 86% of the ... Cell Ltd., in which Elbit Medical holds approximately 30.8% ... majority of Gamida Cell,s shareholders (including Elbit Medical), signed ...
(Date:8/18/2014)... , August 19, 2014 ... cell expansion technologies and therapeutic products, announced today that it ... Pharma AG  ( " Novartis " ... $35 million in Gamida Cell and in return will receive ... The option is exercisable for a limited period of time ...
(Date:8/18/2014)... YORK , Aug. 18, 2014 /PRNewswire/ ... research report is available in its catalogue: ... Biopharmaceutical Markets ... be categorized into three types: chromatography, membranes/filters ... products is increasing and fueling growth of ...
Breaking Medicine Technology:Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 3Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 2Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 3Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 4Bioseparation Systems for Global Biopharmaceutical Markets 2Bioseparation Systems for Global Biopharmaceutical Markets 3Bioseparation Systems for Global Biopharmaceutical Markets 4Bioseparation Systems for Global Biopharmaceutical Markets 5Bioseparation Systems for Global Biopharmaceutical Markets 6Bioseparation Systems for Global Biopharmaceutical Markets 7Bioseparation Systems for Global Biopharmaceutical Markets 8Bioseparation Systems for Global Biopharmaceutical Markets 9Bioseparation Systems for Global Biopharmaceutical Markets 10Bioseparation Systems for Global Biopharmaceutical Markets 11Bioseparation Systems for Global Biopharmaceutical Markets 12
... Cempra Pharmaceuticals today announced results from its Phase ... tolerability of oral administration of our fourth generation ... with oral levofloxacin for the treatment of community-acquired ... CEM-101 demonstrated efficacy comparable to levofloxacin and a ...
... Sept. 15, 2011 Reportlinker.com announces that ... in its catalogue: Global ... http://www.reportlinker.com/p0240543/Global-Blood-Glucose-Test-Strips-Market-2010-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... Test Strips market to grow at a ...
Cached Medicine Technology:Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP) 2Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP) 3Global Blood Glucose Test Strips Market 2010-2014 2
(Date:8/19/2014)... Horizon Blue Cross Blue Shield of New Jersey ... again teaming up during The Barclays at The Ridgewood ... Challenge, and Horizon BCBSNJ will be getting spectators into the ... their own. , Horizon BCBSNJ, the official health care sponsor ... donation to the New Jersey Golf Foundation, an organization that ...
(Date:8/19/2014)... NY (PRWEB) August 19, 2014 ... were named the winner of the 2014 Independent ... took home the first place position in “Product ... marketplace specially-formatted eyeliner, which also includes a lash ... black color, plus lash-boosting technology. , ...
(Date:8/19/2014)... August 19, 2014 Following the completion of ... Hyatt Tampa Bay is proud to debut the highly ... project included a full revamp of all public spaces to ... rooms and suites, an all-new dining experience at 1823 Kitchen ... lobby. , With the introduction of 1823 Kitchen and Bar, ...
(Date:8/19/2014)... Philadelphia, PA, August 19, 2014 Warfarin, the ... competition from new options in the anticoagulant drug ... study documents the rapid adoption of these novel ... NOACs accounted for 62% of all new anticoagulant ... drug costs. Findings are published in The ...
(Date:8/19/2014)... Title Boxing Club Cool Springs is now open. ... away prizes – including an entire year's membership. Sweepstakes ... and click on the “Hit It Hard” Sweepstakes. Once ... enters, you will receive an additional chance to win. ... take advantage of the “Pre-Opening Special” which Includes a ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 3Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 4Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3Health News:Grand Hyatt Tampa Bay Hotel Unveils the Finishing Touches of Its $20 Million Makeover 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 3Health News:Title Boxing Club Cool Springs is Officially Open 2
... CBM ) reports fourth quarter and full year 2008 results ... , Sales increased 0.8% compared ... the impact of foreign currency. Reported sales declined by 6.6% ... Adjusted EBITDA (see attached table) was $10.7 ...
... New Product Development, Marketing and InnovationBEDFORD, Mass., Feb. ... and produced by Insulet Corporation (Nasdaq: ... for the prestigious 2009 Edison Best New Product ... accolades honoring excellence in new product development, marketing, ...
... to better diagnosis, treatment for heart patients , , WEDNESDAY, ... called contrast echocardiography had a significant impact on the ... a new study found. , Echocardiography bounces sound waves ... the moving heart. If that image isn,t clear enough, ...
... than $1000. , ... Eagan, MN (Vocus) February 11, 2009 -- Employees ... United Way of Northeastern Minnesota. A company cookbook was created and ... Iowa. More than 200 cookbooks were sold. , , , ...
... Doctors with Plastic Surgery Services of Fredericksburg ... area to offer LATISSE(TM), the new FDA-approved prescription ... darker, fuller and longer. LATISSE,s maker, Allergan, ... BOTOX(R) and Juvederm(TM). The active ingredient in LATISSE(TM) ...
... doctors at high-volume hospitals do best, study finds , , ... a person surviving a heart attack roughly double ... and facility experienced in the use of angioplasty and ... percutaneous coronary interevention (PCI), which uses angioplasty and a ...
Cached Medicine News:Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 2Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 3Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 4Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 5Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 6Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 7Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 8Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 9Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 10Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 11Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 12Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 13Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 14Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 15Health News:OmniPod(R) Insulin Management System Selected as a Finalist for the 2009 Edison Best New Product Awards(TM) 2Health News:OmniPod(R) Insulin Management System Selected as a Finalist for the 2009 Edison Best New Product Awards(TM) 3Health News:Study Brings Value of Echocardiography Into Focus 2Health News:Company Cookbook Proceeds to Benefit United Way of Northeastern Minnesota 2Health News:Long and Lovely Lashes by LATISSE(TM) Now Available Through Plastic Surgery Services of Fredericksburg 2Health News:Experience Brings Better Angioplasty Outcomes 2
... Based on decades of experience, the SSD-1000 ... ultrasound system. It uses our advanced technologies ... experience. Using the same technology as our ... imaging capabilities in a compact and mobile ...
... Using pulsed radiofrequncy current, ... system quickly heats and ablates ... it in minimal time., RF ... in open surgery, percutaneously, or ...
... a biologically based adhesive supplied as ... consisting of a liquid substrate and ... internal bleeding. When combined ... to a prepared wound and tenaciously ...
... (Human) achieves a secure clot, targeted to ... for hemostasis is needed, when control of ... ligature, and cautery, is ineffective or impractical., ... formulation of human Biologically Active Component (BAC) ...
Medicine Products: